key: cord-0693213-acx9jnqz authors: Siwy, Justyna; Wendt, Ralph; Albalat, Amaya; He, Tianlin; Mischak, Harald; Mullen, William; Latosinska, Agnieszka; Lübbert, Christoph; Kalbitz, Sven; Mebazaa, Alexandre; Peters, Björn; Stegmayr, Bernd; Spasovski, Goce; Wiech, Thorsten; Staessen, Jan A.; Wolf, Johannes; Beige, Joachim title: CD99 and polymeric immunoglobulin receptor peptides deregulation in critical COVID‐19: A potential link to molecular pathophysiology? date: 2021-08-21 journal: Proteomics DOI: 10.1002/pmic.202100133 sha: a5e28e84b52a1555aaeb67e77dc087730558fe8b doc_id: 693213 cord_uid: acx9jnqz Identification of significant changes in urinary peptides may enable improved understanding of molecular disease mechanisms. We aimed towards identifying urinary peptides associated with critical course of COVID‐19 to yield hypotheses on molecular pathophysiological mechanisms in disease development. In this multicentre prospective study urine samples of PCR‐confirmed COVID‐19 patients were collected in different centres across Europe. The urinary peptidome of 53 patients at WHO stages 6–8 and 66 at WHO stages 1–3 COVID‐19 disease was analysed using capillary electrophoresis coupled to mass spectrometry. 593 peptides were identified significantly affected by disease severity. These peptides were compared with changes associated with kidney disease or heart failure. Similarities with kidney disease were observed, indicating comparable molecular mechanisms. In contrast, convincing similarity to heart failure could not be detected. The data for the first time showed deregulation of CD99 and polymeric immunoglobulin receptor peptides and of known peptides associated with kidney disease, including collagen and alpha‐1‐antitrypsin. Peptidomic findings were in line with the pathophysiology of COVID‐19. The clinical corollary is that COVID‐19 induces specific inflammation of numerous tissues including endothelial lining. Restoring these changes, especially in CD99, PIGR and alpha‐1‐antitripsin, may represent a valid and effective therapeutic approach in COVID‐19, targeting improvement of endothelial integrity. The study was supported by the German Federal Ministry of Health acting upon a decree from the German Federal Parliament and by the DEFEAT Pandemics platform of the Federal Ministry of Education and Research (BMBF) to TW. Justyna Siwy and Ralph Wendt contributed equally to this work. prospective study urine samples of PCR-confirmed COVID-19 patients were collected in different centres across Europe. The urinary peptidome of 53 patients at WHO stages 6-8 and 66 at WHO stages 1-3 COVID-19 disease was analysed using capillary electrophoresis coupled to mass spectrometry. 593 peptides were identified significantly affected by disease severity. These peptides were compared with changes associated with kidney disease or heart failure. Similarities with kidney disease were observed, indicating comparable molecular mechanisms. In contrast, convincing similarity to heart failure could not be detected. The data for the first time showed deregulation of CD99 and polymeric immunoglobulin receptor peptides and of known peptides associated with kidney disease, including collagen and alpha-1antitrypsin. Peptidomic findings were in line with the pathophysiology of COVID-19. The clinical corollary is that COVID-19 induces specific inflammation of numerous tissues including endothelial lining. Restoring these changes, especially in CD99, PIGR and alpha-1-antitripsin, may represent a valid and effective therapeutic approach in COVID-19, targeting improvement of endothelial integrity. CD99, COVID-19, endothelial disease, heart failure, kidney disease, PIGR Accumulating evidence indicates that in SARS-CoV2-infection endothelial injury, capillary leakage and renal injury [1] [2] [3] may be a key factor contributing to hospitalisation and mortality [4] Chronic kidney disease (CKD) is connected to endothelial dysfunction [5] and dysregulation of the immune system. Acute kidney injury (AKI) shares molecular links to endothelial traits like, thrombotic microangiopathy and severe sepsis with multi organ dysfunction [6] . As a result of these facts, pathophysiological mechanisms of COVID-19, especially those linked to protein degradation, are expected to be detectable, possibly even enriched in urine peptides. This assumption was supported initially by a preliminary study that enabled identification of urinary peptides significantly affected by SARS-CoV-2 infection, and by COVID-19 disease severity [7] . As a result of these promising findings, a prospective multicenter study was initiated. First results from this study based on 327 subjects demonstrated a significant predictive value of urinary peptides, opening the path forward for a strategy to combine accurate prediction with targeted, personalized intervention [8] . To characterize the molecular impact of the severity of COVID-19, we performed a comprehensive analysis of urinary peptides of COVID-19 patients using capillary electrophoresis-coupled mass spectrometry (CE-MS) and compared the resulting peptide data from patients with critical and mild courses of COVID-19. In a second step, we investigated additional peptidomics data retrieved from the urine peptide database [9] to assess changes observed in (non-COVID-19) patients with diabetic kidney disease (DKD) representing CKD, in AKI, and in heart failure (HF) versus controls. The changes observed in these diseases were subsequently compared to the changes observed in severe COVID-19. Urine samples from 119 SARS-CoV-2 infected patients were collected in the "Prospective Validation of a Proteomic Urine Test for Early and Accurate Prognosis of Critical Course Complications in Patients with SARS-CoV-2 Infection" (CRIT-Cov-U) study, described previously [7] . Samples were prospectively collected within 2 days after a positive Samples were analysed by CE-MS and the generated data processed as described before, including assignment of sequences [9, 11] . In short, urine aliquots were thawed and 700 μL mixed with 700 μL of 2 M urea, 10 mM NH 4 OH containing 0.02 % SDS. Subsequently, samples were ultrafiltered using a Centristat 20 kDa cut-off centrifugal filter device (Satorius, Göttingen, Germany The CE-MS data were analysed using the MosaFinder software [9] . Only signals observed in a minimum of three consecutive spectra with a signal-to-noise ratio > 3 were considered. Data were calibrated utilizing internal standards as reference for mass and migration time by applying global and local linear regression, respectively. Reference signals of 29 abundant peptides were used as internal standards for calibration using linear regression. This procedure was shown to be an easy and reliable method to address both analytical and dilution variances in a single calibration step [12] . All detected peptides are deposited, matched, and annotated in a Microsoft SQL database allowing further statistical analysis. Additional CE-MS datasets were extracted from the urinary proteome database [9] . This database includes >80,000 datasets processed and normalized as described above. This approach results in a highly comparable dataset, with no detectable batch effects [11, 13] . Extracted were datasets of 119 control subjects without COVID-19 disease matched to the full cohort of COVID-19 patients for age, sex, blood pressure, and eGFR (based on the CKD-EPI formula). Furthermore, CE-MS data from patients with diabetic kidney disease, DKD (n = 571) and 374 controls matched for age, sex, blood pressure, and diabetes duration [14] ; 773 datasets from HF patients and 773 matched (for age, sex, blood pressure, kidney function, and diabetes) controls [15] , and 94 datasets from patients with AKI (KDIGO grade 2 and 3) and 348 controls (KDIGO grade 0), matched for age and sex were also extracted from the database. Fluorescence-activated cell sorting (FACS) was performed for COVID- Figure S1 ). Peptides levels across groups as well as flow cytometry data were compared using the Wilcoxon rank sum test. False discovery rate was assessed by the method described by Benjamini and Hochberg [16] . To estimate the relationship between the changes in urinary peptides of different conditions, regression analysis was calculated using MedCalc version 12.7.5.0 (MedCalc Software; Mariakerke, Belgium). Urinary peptide data of patients with critical COVID-19 course (n = 53) were compared to data from mild COVID-19 courses (n = 66). Selected clinical/demographic data that are known to impact the urinary peptidome are given in Table 1 . The statistical analysis returned 593 urinary peptides that were significantly associated with COVID-19 severity (listed in the Table S1 ). To set these observations in context with healthy subjects, we extracted CE-MS data from 119 control subjects without COVID-19 disease from the urinary proteome database, matched to the full cohort of COVID-19 patients for age, sex, blood pressure, and eGFR ( Table 1) . These data, and the changes observed in mild and critical COVID-19 in comparison to the controls are also listed in Table S1 . The distribution of the 593 peptides is presented in Figure 1 , which also depicts the distribution of these peptides in matching controls. As types of collagens, alpha-1-antitrypsin, beta-2-microglobulin, fibrinogen, and protein S100-A9 were prominently found. To assess similarity to other disease, the changes observed when comparing mild to critical disease course were subsequently compared to peptide changes observed in other disease included in the human urinary peptide database [9] : DKD patients (n = 571) were compared to 374 controls matched for age, sex, blood pressure and diabetes duration [14] , 773 datasets from HF patients were compared to 773 matched (for age, sex, blood pressure, kidney function, and diabetes) controls [15] , and 94 patients with AKI (KDIGO grade 2 and 3) were compared to 348 controls (KDIGO grade 0), matched for age and sex [17, 18] . For each peptide, fold change in disease vs. controls was calculated. The results are shown in Figure 2 . Reductions of urinary CD99 and PIGR peptides (negative correlations) were apparently exclusive in severe COVID-19 and not detectable in DKD, AKI, and HF. Significant positive correlations were found between critical COVID-19 and DKD (Figure 2A , R 2 = 0.41) and AKI ( Figure 2B , R 2 = 0.30) but not between critical COVID-19 and HF ( Figure 2C ). The substantial degree of similarity between critical COVID-19 and kidney diseases is also evident from the heatmap shown in Figure 2D (for non-collagen protein fragments) and Figure 2E (for collagen protein fragments), depicting the urinary excretion pattern of the 100 most significant (p-values < 3.0 × 10 -7 ) critical COVID-19 associated peptides. To further investigate the observed reduction of CD99 peptides in critical COVID-19, we assessed CD99 expression on lymphocytes from COVID-19 patients with moderate or severe disease course. Since Figure S1 , respectively. Changes in urinary peptides are specific for distinct pathologies and allow discrimination of different disease aetiologies as demonstrated previously [19] , but also enable definition of shared changes displaying frequently involved processes like endothelial integrity, fibrosis, or inflammation. The exclusive and for the first time warrant further mechanistic studies on the role of this mechanism, for instance using recombinant CD99 or knock-out approaches in cell culture or animal experiments. Two FDA-approved compounds are available, clofarabine and cladribine, which target CD99 function [21] . Both drugs inhibit dimerization of CD99 which would likely have a negative impact on the COVID-19 progression. However, these drugs may be of value in initial experiments to investigate the role of CD99 in COVID- Like CD99, PIGR has not been investigated in the context of COVID- 19 . PIGR was reported reduced in chronic obstructive pulmonary disease [22] , a risk factor for COVID-19 severity. Further investigations of PIGR in COVID-19 patients via for example immunohistochemistry appear justified to confirm the observations in this study, and potentially also indicate opportunities for therapeutic intervention. Deregulation of collagen homeostasis, found in severe COVID-19 patients here, is a well described feature in kidney disease [23] . The interconnection of COVID-19 and kidney injury is now known for several months, initially identified via autoptic findings [3] . Here, for the first time by urinary peptide signature, we provide evidence that these diseases share common features in collagen homeostasis deregulation. The most prominent changes in collagen fragments showed even stronger decrease in critical COVID-19 patients compared to kidney disease patients (Figure 2) . Similarities at molecular level between kidney disease and critical COVID-19 patients were also observed in the regulation of alpha-1-antitripsin, in both cases up-regulated in urine, likely the result of increased degradation. Of note: alpha-1-antitrypsin deficiency is described as major risk factor for critical COVID-19 [24] . Our data also indicate specific association of critical COVID-19 with kidney disease. The molecular changes observed in HF reveal no similarity [25] . It is surprising that the very prominent changes observed in urinary peptides were not described in other studies that investigated the impact of COVID-19 disease course on the proteome [26, 27] . However, these studies in general were of low power, and, in addition, investigated blood as a potential source of biomarkers. Given the high variability that is a result of blood sampling, in part due to activation of proteases in the coagulation cascade [28] and the low number of subjects involved in the studies reported, the comparison between the results may be interpreted as supporting approaches that exploit more stable biospecimen (as e.g. urine) and that are based on a large number of independent samples, to provide sufficient statistical power. In conclusion, the data presented here strongly suggest that severe COVID-19 is associated and may in part be the result of distinct molecular changes of endogenous proteins. Restoring these changes, especially in CD99, PIGR and alpha-1-antitripsin, may represent a valid and effective therapeutic approach in COVID-19, targeting improvement of endothelial integrity. SARS-CoV-2 renal tropism associates with acute kidney injury COVID-19-associated nephritis: Early warning for disease severity and complications? Multiorgan and renal tropism of SARS-CoV-2 Factors associated with COVID-19-related death using OpenSAFELY The dysfunctional endothelium in CKD and in cardiovascular disease: Mapping the origin(s) of cardiovascular problems in CKD and of kidney disease in cardiovascular conditions for a research agenda Acute kidney injury Urinary proteomics associates with COVID-19 severity : pilot proof-of-principle data and design of a multicentric diagnostic study Peptidomics and proteomics based on CE-MS as a robust tool in clinical application: The past, the present, and the future World Health Organization. Ordinal scale for clinical improvement. 2020. WHO R&D Blueprint Novel Coronavirus Technical aspects and inter-laboratory variability in native peptide profiling: The CE-MS experience Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy A urinary proteome-based classifier for the early detection of decline in glomerular filtration Urinary peptides in heart failure: a link to molecular pathophysiology Addressing the challenge of defining valid proteomic biomarkers and classifiers Proteomic biomarkers for the early detection of acute kidney injury Acute kidney injury prediction in cardiac surgery patients by a urinary peptide pattern: A case-control validation study Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis von Willebrand factor multimer formation contributes to immunothrombosis in coronavirus disease 2019 Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99 Polymeric immunoglobulin receptor down-regulation in chronic obstructive pulmonary disease. Persistence in the cultured epithelium and role of transforming growth factor-β Diagnosis and prediction of CKD progression by assessment of urinary peptides α1-Antitrypsin deficiency and the risk of COVID-19: An urgent call to action In-hospital care in acute heart failure during the COVID-19 pandemic: Insights from the German-wide Helios hospital network Ultrahigh-throughput clinical proteomics reveals classifiers of COVID-19 infection Ultra-fast proteomics with Scanning SWATH Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery the Supporting Information section at the end of the article. How to cite this article